Subscribe
shutterstock_609476021_ken_wolter
Ken Wolter / Shutterstock.com
25 April 2019Generics

Insurer accuses Janssen of sham lawsuits to stop cancer generic

A US health insurance provider is suing a subsidiary of Johnson & Johnson for filing “sham” patent litigation in a bid to stop generic forms of a prostate cancer treatment from entering the market.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
J&J to buy surgical robotics company for $3.4bn
18 February 2019   Johnson & Johnson has announced plans to strengthen its robotics programme with the addition of Silicon Valley-based Auris Health to its business.
Big Pharma
City of Baltimore accuses Janssen of delaying generics
23 May 2019   Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, is being sued for “unlawfully” delaying generic competition to Zytiga, its branded cancer medication.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
J&J to buy surgical robotics company for $3.4bn
18 February 2019   Johnson & Johnson has announced plans to strengthen its robotics programme with the addition of Silicon Valley-based Auris Health to its business.
Big Pharma
City of Baltimore accuses Janssen of delaying generics
23 May 2019   Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, is being sued for “unlawfully” delaying generic competition to Zytiga, its branded cancer medication.

More on this story

Americas
J&J to buy surgical robotics company for $3.4bn
18 February 2019   Johnson & Johnson has announced plans to strengthen its robotics programme with the addition of Silicon Valley-based Auris Health to its business.
Big Pharma
City of Baltimore accuses Janssen of delaying generics
23 May 2019   Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, is being sued for “unlawfully” delaying generic competition to Zytiga, its branded cancer medication.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility